New Product in Development Looks to Help Patients with Clostridium Difficile

Video

In the world of gastrointestinal conditions clostridium difficile, or c-diff is becoming a more common condition confronting doctors. Finding the best treatment method remains to be seen.

In the world of gastrointestinal conditions clostridium difficile, or c-diff is becoming a more common condition confronting doctors. Finding the best treatment method remains to be seen.

Lee Jones, the President and CEO of Rebiotix and Erik Dubberke, MD, from the University of Washington School of Medicine discussed the development of one such potential treatment option being developed during the annual ID Week conference in San Diego.

Related Videos
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Credit: Cleveland Clinic
Anthony Lembo, MD | Credit: Cleveland Clinic
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Ali Rezaie, MD | Credit: X
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
Paul Feuerstadt, MD | Yale School of Medicine
© 2024 MJH Life Sciences

All rights reserved.